Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2392106A
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2392106A is an investigational recombinant protein-based vaccine developed by GSK (GlaxoSmithKline) for the prevention of Staphylococcus aureus infections. It is one of several related candidate vaccines evaluated in clinical studies to assess safety, reactogenicity, and immunogenicity in healthy adults. The vaccine is composed of multiple recombinant protein antigens designed to elicit an immune response against S. aureus, a major cause of hospital- and community-acquired infections[1][3]. The primary mechanism involves stimulating the immune system to recognize and respond to S. aureus antigens, thereby providing protective immunity.
Beyond the preview
Go deeper on GSK2392106A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2392106A.